Short-Acting Insulin

04/01/2013 - "Use of the rapid-acting insulin analogue aspart was associated with a reduced incidence of macrovascular outcomes in type 2 diabetes in general practices. "
11/01/2012 - "Prescription of the rapid-acting insulin analog glulisine was associated with a reduced incidence of macro- and microvascular outcomes in Type 2 diabetes under real-life conditions. "
06/01/2012 - "1. Few studies have evaluated the pharmacokinetics of rapid-acting insulin analogues in patients with Type 2 diabetes, especially under clinical conditions. "
12/01/2010 - "This study assessed the kinetics of a short-acting insulin analog in obese subjects with type 2 diabetes. "
04/11/2022 - "Rapid-acting insulin analogues: Theory and best clinical practice in type 1 and type 2 diabetes."

12/13/2022 - "Up to one third of children and adolescents with type 1 diabetes injected rapid-acting insulin analogues after a meal. "
01/01/2018 - "We performed a comprehensive literature search to review the published data, focusing on the use of rapid-acting insulin analogues in patients with Type 1 diabetes. "
04/01/2016 - "Administration of rapid-acting insulin according to an individualized algorithm reduced the hyperglycaemia associated with morning resistance exercise without causing hypoglycaemia in the 2 h post-exercise period in people with Type 1 diabetes."
04/01/2016 - "To develop an algorithm that delivers an individualized dose of rapid-acting insulin after morning resistance exercise to counter post-exercise hyperglycaemia in individuals with Type 1 diabetes. "
04/01/2016 - "Algorithm that delivers an individualized rapid-acting insulin dose after morning resistance exercise counters post-exercise hyperglycaemia in people with Type 1 diabetes."

01/01/2018 - "Systematic implementation of low-cost interventions successfully resulted in measurable improvement in timely rapid-acting insulin administration for hospitalized patients with CFRD and lower rates of severe hypo- and hyperglycemia on the unit. "
06/01/2023 - "Studies permit rapid-acting insulin until a few hours before the MMTT, and thus do not exclude overnight hyperglycemia prior to testing. "
01/01/2018 - "Euglycemia was maintained for 3h followed by induction of hyperglycemia and simultaneous bolus of rapid acting insulin. "
05/01/2015 - "Delays in the time-action profiles of premeal boluses of rapid-acting insulin analogs contribute to early postmeal hyperglycemia in patients with diabetes. "
07/01/1998 - "Earlier basal NPH dosage alone does not ameliorate the nighttime hyperglycemia of short-acting insulin analog regimens."

01/01/2023 - "Rapid-acting insulin analogs were associated with reduced severe hypoglycemia, though there were more patients with mild to moderate hypoglycemia. "
01/01/2018 - "Approximately 20 hours after her last rapid-acting insulin exposure, she had an episode of fasting hypoglycemia (33 mg/dL on glucometer). "
06/30/2017 - "Therefore, to avoid hypoglycemia, the preexercise short-acting insulin dose must be reduced for safety reasons. "
02/01/2015 - "Short-acting insulin analogues have faster absorption and long-acting analogues have a lower risk of hypoglycemia. "
06/15/2014 - "Short acting insulin analogues (SAIA) have been synthesized to improve the chronic treatment of patients with diabetes but, because of the pharmacokinetic characteristics that include shorter on-set and off-set, they can be effectively used also in ICU patients and have the potential to be associated with a more limited risk of inducing episodes of iatrogenic hypoglycemia. "

01/01/2017 - "Simpler protocols using subcutaneous rapid-acting insulin analogues for mild/moderate diabetic ketoacidosis treatment have proven to be safe and effective, but further studies are required to confirm these results. "
01/01/2021 - "Subcutaneous Rapid-acting Insulin Analogs for Diabetic Ketoacidosis."
01/01/2020 - "The use of rapid-acting insulin analogs as routes of administration other than IV has never been described for the treatment of dogs with diabetic ketoacidosis (DKA). "
01/21/2016 - "To assess the effects of subcutaneous rapid-acting insulin analogues for the treatment of diabetic ketoacidosis. "
01/21/2016 - "Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis."